Fewer Proprietary Drug Names Rejected With FDA, Industry On Same Page
This article was originally published in The Tan Sheet
Executive Summary
After several false starts, FDA and the pharma industry appear to be on the same page about vetting potential brand names for new drugs. FDA’s rate of rejecting proposed brand names has dropped from 50% or higher when the decade began to about 25%, according to Office of Surveillance and Epidemiology data.